ClinicalTrials.gg
Active, not recruitingNCT04176588Updated Jan 9, 2024

A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Etrasimod and Placebo in Moderately to Severely Active Ulcerative Colitis, sponsored by Everstar Therapeutics Limited. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Everstar Therapeutics Limited · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
4th of 12
341 · median 195
Started
2019
with 2 others
Phase 3
5 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
1 of 12
Everstar Therapeutics Limited

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 6th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.

Condition or disease: Ulcerative Colitis Intervention/treatment: Drug: Etrasimod Drug: Placebo Phase: Phase 3

03

Conditions studied

  • Moderately to Severely Active Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A documented of diagnosis with UC at least 3 months prior to screening.
  2. Have active UC confirmed by endoscopy with ≥ 10 cm rectal involved.

Exclusion criteria

Exclusion Criteria:

  1. Have severe extensive colitis
  2. Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease
  3. Diagnosis of microscopic colitis, ischemic colitis, infection colitis or colonic mucosal dysplasia
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
341 participants (actual)

Study arms

  • Experimental
    Experimental: Etrasimod 2mg

    2mg/tablet, administratered orally, once daily

    Drug: Etrasimod

  • Placebo comparator
    Placebo Comparator: Placebo

    matching tablet, administratered orally, once daily

    Drug: Placebo

  • Experimental
    Etrasimod 2mg (optional open-label extension period)

    2mg/tablet, administratered orally, once daily

    Drug: Etrasimod

Interventions

  • Drug:Etrasimod Tablet other name:APD334

  • DrugPlacebo

    Drug:placebo Tablet

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With Clinical Remission Assessed by modified Mayo score(mMS)

    Clinical remission per mMS(endoscopy, rectal bleeding, stool frequency), ranging from 0-9 (normal to severe)

    Time frame: induction period week 12

  2. Proportion of Subjects With Clinical Remission Assessed by modified Mayo score(mMS)

    Clinical remission per mMS, ranging from 0-9 (normal to severe)

    Time frame: Maintenance period week 40

Secondary outcomes

  1. Proportion of Subjects Achieving Endoscopic Improvement Assessed by endoscopic subscore

    Endoscopic improvement per endoscopy subscore, ranging from 0 to 3 (normal to severe)

    Time frame: induction period week 12

  2. Proportion of Subjects with Clinical Response Assessed by modified Mayo score(mMS)

    Clinical response per mMS, ranging from 0 to 9 (normal to severe).

    Time frame: induction period Week 12

  3. Proportion of Subjects Achieving Endoscopic Improvement Assessed by endoscopic subscore

    Endoscopic improvement per endoscopy subscore, ranging from 0 to 3 (normal to severe)

    Time frame: Maintenance period Week 40

  4. Proportion of Subjects with Clinical Response Assessed by modified Mayo score(mMS)

    Clinical response per mMS, ranging from 0 to 9 (normal to severe)

    Time frame: Maintenance period Week 40

  5. Proportion of Subjects who achieve symptomatic response over time

    Symptomatic response per paritial Mayo score(rectal bleeding, stool frequency), ranging from 0-6(normal to severe)

    Time frame: Open label treatment period up to 40 Weeks

  6. Proportion of Subjects who achieve Symptomatic Remission over time

    Symptomatic remission per paritial Mayo score, ranging from 0-6(normal to severe)

    Time frame: Open label treatment period up to 40 Weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Jul 2024, 58 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 58 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Nov 25, 2019
StartActual
Sep 10, 2019
Primary completionEst.
Jul 2024
CompletionEst.
Oct 2024
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04176588
Lead sponsor
Everstar Therapeutics Limited
Responsible party
Sponsor
First posted
Nov 25, 2019
Start date
Sep 10, 2019
Primary completion
Jul 2024 (estimated)
Completion
Oct 2024 (estimated)
Last update
Jan 9, 2024

Study contacts

Kaichun Wu
principal investigator · The First Affiliated Hospital of Fourth Military Medical University, PLA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion